Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21597614 | 0.80 | NPC1 (0.41) | MAPK1ALDH1A1ADORA2AADORA1HCAR1 | |
| SCHEMBL544340 | 0.79 | MAPK1 (0.41) | POLBMAPK1TSHRHTTKMT2A | |
| SCHEMBL31398276 | 0.76 | TSHR (0.43) | POLBPKMALDH1A1TSHRHCAR1 | |
| SCHEMBL16278195 | 0.76 | PKM (0.37) | POLBPKMALOX15TSHRFAAH | |
| SCHEMBL31398277 | 0.76 | TSHR (0.43) | POLBPKMALDH1A1TSHRHCAR1 | |
| SCHEMBL14204021 | 0.76 | PKM (0.37) | PKMALDH1A1TSHRFAAHMGLL | |
| SCHEMBL15022265 | 0.69 | MAPK9 (0.60) | ALDH1A1TSHRHSD17B10NPC1RAB9A | |
| SCHEMBL15555209 | 0.64 | CYP1A2 (0.52) | POLBPKMALOX15MAPK1ALDH1A1 | |
| SCHEMBL12491375 | 0.63 | OPRD1 (0.46) | PKMALOX15ALDH1A1TDP1GAA | |
| SCHEMBL14204081 | 0.63 | MAPK9 (0.32) | MAPK1ALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133512-A1 | N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS | HOFFMANN-LA ROCHE INC. | 2015-05-14 | — | — | US | disclosed |
| US-20150133512-A1 | N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS | HOFFMANN-LA ROCHE INC. | 2015-05-14 | — | — | US | disclosed |
| US-20150133512-A1 | N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS | HOFFMANN-LA ROCHE INC. | 2015-05-14 | — | — | US | disclosed |
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| CN-104395299-A | N-aryltriazole compounds as lpar antagonists | HOFFMANN LA ROCHE | 2015-03-04 | — | — | CN | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2013025733-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
| CN-1035817-C | Triazolyl-substituted tertiary amino compounds and their salts | YAMANCUCHI PHARMACEUTICAL CO L (JP) | 1997-09-10 | — | — | CN | disclosed |
| CN-1069974-A | Tertiary amine compound and salt thereof that triazolyl replaces | YAMANCUCHI PHARMACEUTICAL CO L (JP) | 1993-03-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | POLB 4247/4885PKM 2118/4885ALOX15 183/4885 |
| US-20150133512-A1 | N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS | LPAR1, LPAR2, LPAR3 | POLB 3191/4885PKM 3751/4885ALOX15 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.